ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) Debt Components
- 2025-03-31: Long-term Debt, Excluding Current MaturitiesUSD $15.00M; Long-term Debt, Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2023-09-30: Long-term Debt, Excluding Current MaturitiesUSD $20.00M; Long-term Debt, Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2022-12-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Debt, Current MaturitiesUSD $60.66M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2022-09-30: Long-term Debt, Excluding Current MaturitiesUSD $32.04M; Long-term Debt, Current MaturitiesUSD $27.70M; Long-term DebtUSD $13.30M; Long-Term Debt, Maturity, Year OneUSD $10.30M.
ARCTURUS THERAPEUTICS HOLDINGS INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Long-term Debt, Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | $15.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $20.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $60.66M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $32.04M | $27.70M | $13.30M | $10.30M | (m) | (m) | (m) | $3.00M |
| 2022-06-30 | $35.76M | $27.02M | $15.30M | $10.30M | (m) | (m) | (m) | $5.00M |
| 2022-03-31 | $39.23M | $24.26M | $15.30M | $10.30M | (m) | (m) | (m) | $5.00M |
| 2021-12-31 | $40.63M | $22.47M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $15.30M | $6.67M | $8.63M | (m) | (m) | (m) |
| 2021-09-30 | $42.34M | $18.48M | $15.30M | $6.67M | $8.63M | (m) | (m) | (m) |
| 2021-06-30 | $56.31M | $5.00M | $15.30M | $7.50M | $6.55M | (m) | (m) | $1.25M |
| 2021-03-31 | $58.15M | $3.12M | $15.30M | $7.50M | $6.55M | (m) | (m) | $1.25M |
| 2020-12-31 | $13.85M | $1.25M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $15.30M | $1.25M | $7.50M | $6.55M | (m) | (m) |
| 2020-09-30 | $15.08M | (m) | (m) | $1.30M | $7.50M | $6.50M | (m) | $0.00 |
| 2020-06-30 | $15.06M | (m) | (m) | (m) | $1.30M | $7.50M | $6.70M | $0.00 |
| 2020-03-31 | $15.03M | (m) | (m) | (m) | $4.00M | $6.00M | $5.50M | $0.00 |
| 2019-12-31 | $14.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $15.45M | (m) | $4.00M | $6.00M | $5.45M | (m) |
| 2019-09-30 | $10.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $9.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $9.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |